Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 10/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24862650 | 0.89 | SLC16A3 (0.43) | SLC16A3MAPK1 | |
| SCHEMBL24109641 | 0.89 | SLC16A3 (0.47) | SLC16A3GRM5 | |
| SCHEMBL24110555 | 0.89 | SLC16A3 (0.44) | SLC16A3MAPK1 | |
| SCHEMBL25035676 | 0.86 | SLC16A3 (0.43) | SLC16A3GRM5MAPK1 | |
| SCHEMBL22134722 | 0.85 | GRM5 (0.41) | GRM5 | |
| SCHEMBL25037550 | 0.84 | SLC16A3 (0.56) | SLC16A3 | |
| SCHEMBL24109655 | 0.83 | SLC16A3 (0.43) | SLC16A3MAPK1 | |
| SCHEMBL22134792 | 0.82 | SLC16A3 (0.42) | SLC16A3MAPK1 | |
| SCHEMBL24110472 | 0.81 | SLC16A3 (0.46) | SLC16A3 | |
| SCHEMBL22134669 | 0.81 | SLC16A3 (0.38) | SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-02-16 | — | — | US | disclosed |
| EP-3898588-B1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-01-11 | — | — | EP | disclosed |
| WO-2021249969-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF CANCER DISEASES | MERCK PATENT GMBH (DE) | 2021-12-16 | — | — | WO | disclosed |
| WO-2020127960-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | BRCA1, MYC, PCNA | SLC16A3 3198/4885GRM5 4309/4885MAPK1 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.